<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01917695</url>
  </required_header>
  <id_info>
    <org_study_id>GRHCO-01</org_study_id>
    <nct_id>NCT01917695</nct_id>
  </id_info>
  <brief_title>Study on Early Stage Bulky Cervical Cancers</brief_title>
  <official_title>Randomised Phase III Clinical Trial on Concurent Chemoradiation vs. Neoadjuvant Chemoradiation and Surgery vs. Neoadjuvant Chemotherapy and Surgery in Early Stage Bulky Cervical Cancers (FIGO Stages IB2, IIA2 and IIB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajkumar Kottayasamy Seenivasagam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Government Royapettah Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to establish the role of neoadjuvant chemotherapy and chemo
      irradiation in carcinoma cervix and to compare its results with the concurrent chemo
      irradiation in terms of overall survival, disease free survival and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early stage bulky cancers of the cervix, (defined as FIGO Stages IB2, IIA2 and IIB) form a
      distinctive subset of &quot;curable&quot; cervical cancers with good 5 year survival rates with
      adequate treatment. Concurrent chemo radiation with or without salvage surgery is at present
      the standard of care for this group of cervical cancers. However, when pelvic recurrences
      occur, the morbidity of salvage surgery after radiotherapy, especially brachytherapy is often
      higher than the morbidity of salvage radiotherapy following radical surgery. The advantages
      of downsizing the disease without the use of brachytherapy are tempting and open a completely
      new philosophy in radical treatment for &quot;curable&quot; early stage bulky cancers of the cervix.
      This approach is appealing especially in developing countries where the load of cervical
      cancers is high and radiotherapy (brachytherapy) resources are scarce.

      The results of two Phase II trials conducted at Govt. Royapettah Hospital, Chennai
      (Neoadjuvant Chemotherapy followed by Radical Hysterectomy: Cisplatin + 5FU vs. Cisplatin
      +Paclitaxel) and at Govt. General Hospital,Chennai (Neoadjuvant Chemoradiation with weekly
      cisplatin and 50 EBRT followed by radical Hysterectomy) and one retrospective study (
      Preoperative 50 GY EBRT followed by Radical Hysterectomy) have shown similar response rates
      and acceptable toxicity profiles when compared to concurrent chemoradiation (EBRT +
      Brachytherapy+ Chemotherapy). Similar studies have been published elsewhere with similar
      results.

      With this in mind we are planning to conduct a Phase III Randomised control trial comparing
      Neoadjuvant Chemotherapy + Radical Hysterectomy and Neoadjuvant Chemoradiation + Radical
      Hysterectomy with concurrent chemoradiation in this subset of cervical cancers
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall and Disease free Survival</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall and Disease free Survival</measure>
    <time_frame>5 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Adverse reactions and complications</measure>
    <time_frame>Less than 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SubAcute Adverse reactions and complications</measure>
    <time_frame>10 weeks - 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Adverse reactions and complications</measure>
    <time_frame>6 months to 5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3,5 years</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Carcinoma Cervix</condition>
  <arm_group>
    <arm_group_label>Concurrent Radical Chemoradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel(175 mg/sq.m) + Cisplatin (75 mg/sq.m) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT + Brachytherapy (7Gy HDR x 3 doses) All to be completed within 8-10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant Chemoradiation + Radical Hysterectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel(175 mg/m2) + Cisplatin(75 mg/m2) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT - completed within 5 weeks Radical Hysterectomy - 3 weeks after completion of RT All to be completed within 8-10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant Chemotherapy + Radical Hysterectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel(175 mg/m2) + Cisplatin (75 mg/m2) chemotherapy - 3 cycles of 3 weekly cycle Radical Hysterectomy - 3 weeks after completion of chemotherapy All to be completed within 8-10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>cisplatin 75 mg/m2 Paclitaxel 175 mg/m2</description>
    <arm_group_label>Concurrent Radical Chemoradiation</arm_group_label>
    <arm_group_label>Neoadjuvant Chemoradiation + Radical Hysterectomy</arm_group_label>
    <arm_group_label>Neoadjuvant Chemotherapy + Radical Hysterectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiotherapy</intervention_name>
    <description>50 Gy/2 Gy/25 # external beam RT to cervix. four field technique. given concurrently with chemotherapy weeks 1 - 5</description>
    <arm_group_label>Concurrent Radical Chemoradiation</arm_group_label>
    <arm_group_label>Neoadjuvant Chemoradiation + Radical Hysterectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy</intervention_name>
    <description>Ir - 192 HDR Brachytherapy - intracavitary. 7Gy x 3#. given after completion of chemoRT.</description>
    <arm_group_label>Concurrent Radical Chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical Hysterectomy</intervention_name>
    <description>Type III Radical Hysterectomy + Bilateral Pelvic Node Dissection</description>
    <arm_group_label>Neoadjuvant Chemoradiation + Radical Hysterectomy</arm_group_label>
    <arm_group_label>Neoadjuvant Chemotherapy + Radical Hysterectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically confirmed bulky cervical Squamous cell carcinoma (FIGO
             stage IB2, II A2, IIB).

          2. Age 18-60 years

          3. Karnofsky performance status of ≥70%; ECOG PS ≤ 2

        Exclusion Criteria:

          1. Nonsquamous Histologies

          2. Other systemic diseases, comorbidities precluding full participation in the study

          3. Concomitant treatment with any experimental drug

          4. Pregnant or nursing women

          5. Previous or concomitant malignant diseases other than non-melanoma skin cancer

          6. Previous radiation to the pelvis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajaraman Ramamurthy, MS MCh</last_name>
    <role>Study Chair</role>
    <affiliation>centre for oncology, Government Royapettah Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajaraman Ramamurthy, MS MCh</last_name>
    <phone>+919444046168</phone>
    <email>rajaanu1@rediffmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Subbiah Shanmugam, Ms MCh</last_name>
    <phone>+919360206030</phone>
    <email>subbiah_doctor@yahoo.co.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Government Royapettah Hospital</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600014IndiaNaduI6</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajaraman Ramamurthy, MS MCh</last_name>
      <phone>+919444046168</phone>
      <email>rajaanu1@rediffmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Subbiah Shanmugam, MS MCh</last_name>
      <phone>+919360206030</phone>
      <email>subbiah_doctor@yahoo.co.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Rajaraman Ramamurthy, MS MCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Subbiah Shanmugam, MS MCh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2013</study_first_submitted>
  <study_first_submitted_qc>August 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2013</study_first_posted>
  <last_update_submitted>August 11, 2015</last_update_submitted>
  <last_update_submitted_qc>August 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Government Royapettah Hospital</investigator_affiliation>
    <investigator_full_name>Rajkumar Kottayasamy Seenivasagam</investigator_full_name>
    <investigator_title>MCh Surgical Oncology trainee</investigator_title>
  </responsible_party>
  <keyword>Bulky cervical cancers</keyword>
  <keyword>Neoadjuvant Chemotherapy</keyword>
  <keyword>Neoadjuvant Chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

